A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
SARS-CoV-2 RNA (COVID-19) and Respiratory Pathogen Panel, Qualitative NAAT
Test Code31687
CPT Codes
87635, 87633, 87486, 87581<br><br><strong>To meet regulatory reporting requirements for COVID-19 testing, the patient's address, phone number and other demographic details are required for this order.</strong>
Includes
See Clinical Significance
Preferred Specimen
1 nasopharyngeal swab collected in 3 mL VCM or UTM
Minimum Volume
1 swab in 0.5 mL transport
Instructions
Quest Diagnostic Patient Service Centers and Quest in-office phlebotomists do not collect respiratory specimens, including those from patients suspected to have COVID-19.
Cold packs/pouches must be used if placing specimens in a lockbox for courier pick-up. STAT pick-up cannot be ordered for this test.
See the COVID/Flu Specimen Collection Guide for specific acceptable container types.
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: Unacceptable
Refrigerated: 5 days
Frozen: Acceptable
Refrigerated: 5 days
Frozen: Acceptable
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Calcium alginate swabs • Cotton swabs with wooden shaft • Amies liquid or gel transport used for bacterial cultures • Swab in Saline or PBS • Sources other than nasopharyngeal
Methodology
Nucleic Acid Amplification Test (NAAT)
FDA Status
This test has been authorized by the FDA under an Emergency Use Authorization (EUA) for use by authorized laboratories.
Setup Schedule
Sets up 7 days a week.
Report Available
Reports in 1 to 3 days.
Clinical Significance
This test panel is for detection and identification of specific pathogen nucleic acids from individuals exhibiting signs and symptoms of respiratory infection with SARS-CoV-2, or other respiratory viruses and some bacterial pathogens.
This test is intended to be performed on respiratory specimens collected from individuals who meet the Centers for Disease Control and Prevention (CDC) clinical and/or Epidemiological criteria for COVID-19 testing.
For details visit: https://www.cdc.gov/coronavirus/2019-ncov/hcp/index.html.
This test is used for the detection of the following respiratory pathogens:
SARS-CoV-2 (COVID-19)
Influenza A
Influenza A subtype H1
Influenza A subtype H3
Influenza B
Human Parainfluenza Virus (HPIV) 1
Human Parainfluenza Virus (HPIV) 2
Human Parainfluenza Virus (HPIV) 3
Human Parainfluenza Virus (HPIV) 4
Rhinovirus/Enterovirus
Human Metapneumovirus (HMPV)
Human Respiratory Syncytial Virus (HRSV) A
Human Respiratory Syncytial Virus (HRSV) B
Adenovirus
Coronavirus 229E
Coronavirus OC43
Coronavirus NL63
Coronavirus HKU1
Human Bocavirus
Chlamydophila pneumoniae
Mycoplasma pneumoniae
The results of this assay should be used in conjunction with other clinical and laboratory findings.
Click here to see turnaround time
This test is intended to be performed on respiratory specimens collected from individuals who meet the Centers for Disease Control and Prevention (CDC) clinical and/or Epidemiological criteria for COVID-19 testing.
For details visit: https://www.cdc.gov/coronavirus/2019-ncov/hcp/index.html.
This test is used for the detection of the following respiratory pathogens:
SARS-CoV-2 (COVID-19)
Influenza A
Influenza A subtype H1
Influenza A subtype H3
Influenza B
Human Parainfluenza Virus (HPIV) 1
Human Parainfluenza Virus (HPIV) 2
Human Parainfluenza Virus (HPIV) 3
Human Parainfluenza Virus (HPIV) 4
Rhinovirus/Enterovirus
Human Metapneumovirus (HMPV)
Human Respiratory Syncytial Virus (HRSV) A
Human Respiratory Syncytial Virus (HRSV) B
Adenovirus
Coronavirus 229E
Coronavirus OC43
Coronavirus NL63
Coronavirus HKU1
Human Bocavirus
Chlamydophila pneumoniae
Mycoplasma pneumoniae
The results of this assay should be used in conjunction with other clinical and laboratory findings.
Click here to see turnaround time